Competition Regulation and Recombinant Drugs in India
DOI:
https://doi.org/10.5912/jcb609Keywords:
competition, recombinant drugs, SCP modelAbstract
The recombinant drug industry is growing at almost 20% rate in India. The long term growth of this sector depends upon the innovation as well as competition and market. The structure, conduct and performance of firms in market plays a very important role in predicting the future of innovation and competition in market. The present paper analyses the structure-conduct-performance paradigm in the context of recombinant drug sector in India. The analysis reveals that R&D, distribution chains and advertisement has significant effect on the profits of firms in the recombinant drug sector.
References
Bhupinder Singh Sekhon, Biopharmaceuticals: an overview, Thai J. Pharm. Sci. 34 (2010) 1-19; Massimo Riccaboni, Biopharmaceuticals Availability, Diffusion, Sustainability available at http://www.oecd.org/science/scienceandtechnologypolicy/37838005.pdf.
Association of Biotechnology Led Enterprises (ABLE), PriceWaterCoopers Report, Leadership in Affordable Therepeutic Products: A Biopharma Strategy for India available at http://www.ableindia.in/admin/attachments/reports/reports17_Vision%202020%20Bio%20Pharma%20Strategy%20Report.pdf last visited on 22nd Februaury 2013.
Available at http://envfor.nic.in/divisions/csurv/biosafety/recombinant_therapeutics_approved.htm.
(BioSpectrum-ABLE top 20 survey 2012)
Nayantara Som, India on biologics trail, http://www.biospectrumindia.commakesections.asp/1202131.asp
http://archive.biospectrumasia.com/content/206011377.asp
http://www.bharatbiotech.com/2005_sep15.htm.
N Sahoo, P Manchikanti, Recombinant Drug Development, Regulation, and Commercialization: An Indian Industry Perspective, BioDrugs, 2011
J.S. Bain, Industrial Organisation, Wiley, N. Y., 1959; Christian Lennartz, Marietta Haffner and Michael Oxley, Competition between social and market renting: a theoretical application of the structure-conductperformance paradigm, J Hous and the Built Environ (2012) 27:453–471; Bain JS (1951) Relation of profit rate to industry concentration: American Manufacturing, 1936–1940. Q J Econ 65:293–324
Scherer and Ross 1990, ndustrial market structure and economic performance, Houghton Mifflin (Boston).
See G. J. Stigler, A Theory of Oligopoly, Journal of Political Economy, 72 (1964), pp. 44-61 p. 252-281.
M. A. J. Farrell, The Measurement of Productive Efficiency, J. R. S. S., 120 (1957), Series A.
http://envfor.nic.in/divisions/csurv/biosafety/recombinant_therapeutics_approved.htm
Mashelkar Committee Report on Recombinant Sector.
http://www.nppaindia.nic.in/index1.html
WHO essential medicine price list, available on http://www.who.int/mediacentre/factsheets/fs325/en/index.html last accessed on 26th February 2013.
WHO Model Lists of Essential, The current versions are the 17th WHO Essential Medicines List and the 3rd WHO Essential Medicines List for Children updated in March 2011, Medicineshttp://www.who.int/medicines/publications/essentialmedicines/en/index.html
ABLE Report 2011.
http://www.seruminstitute.com/content/products/product_list.htm.
US Department of Justice merger enforcement, available on http://www.justice.gov/atr/public/guidelines/hhi.html last visited on 11th February 2013.
William M Landes and Richard A. Posner (1981), Market Power in Antitrust Cases, Harvard Law Review, 94(5), March 937-96.
Lerner J. (1934), The Concept of Monopoly and the Measurement of Monopoly Power, The Review of Economic Studies, Vol. 1, No. 3, pp. 157-175
Emerging Healthcare Issues: Follow on Biologic Drug Competition, FTC Report June 2009, available at http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf.
Video of the Subcommittee on Health held a hearing on a new Federal Trade Commission (FTC) report titled, "Emerging Health Care Issues: Follow-on Biologic Drug Competition" June 11, 2009. The report states FTC findings with respect to its investigation into the effects of a follow-on biologics pathway on competition and innovation. In particular, the report discusses whether additional incentives in addition to patents and pricing, are needed to ensure continued innovation in the biologics market.
available on http://www.youtube.com/watch?v=zY3R-8LEuuQ.
Biologics, Biosimilar Market Overview, AvesthgenBringing Science to Life Report.
